Takeda and HUTCHMED Announce New Drug Application NDA for Fr

Takeda TSE4502NYSETAK and HUTCHMED China Limited NasdaqAIMHCM HKEX13 HUTCHMED today announced that the U.S. Food and Drug Administration FDA has granted priority review of the New Drug Application NDA for fruquintinib a highly selective and potent inhibitor of vascular endothelial growth factor receptors VEGFR 1 2 and 3 for the treatment of adult patients with previously treated metastatic colorectal cancer CRC.

Related Keywords

United Kingdom , Hong Kong , United States , Australia , Belgium , Cairo , Al Qahirah , Egypt , Japan , Shanghai , China , American , Belgian , Japanese , British , Jun Saito , Mark Lee , Sara Noonan , Michael Shi , Ahcene Djaballah , Jemma Nash , Zhou Yi , Ben Atwell Alex Shaw , Gastroenterol Hepatol , Annie Cheng , Awny Farajallah , Exchange Commission , Stock Exchange Of Hong Kong , Drug Administration , International Agency For Research On Cancer , Journal Of The American Medical Association , International Media , Nasdaq , Global Medical Affairs Oncology At Takeda , Linkedin , China Limited Nasdaq , European Society For Medical Oncology , Solebury Strategic Communications , Takeda Pharmaceutical Company Limited , Clinical Cancer Research , Florham Park , Prescription Drug User Fee Act , Target Action Date Set , Results From , New Drug Application , Global Medical Affairs Oncology , Chief Medical Officer , American Medical Association , European Society , Medical Oncology , International Agency , Annual Report , Securities Litigation Reform Act , Stock Exchange , Cancer Res , Cancer Biol , Overall Survival , Cancer Statistics , Mortality Worldwide , Rev Gastroenterol Hepatol , Colorectal Cancer , Winding Road From Negative Predictive Factor , Positive Actionable , Media Contact , Media Contacts , Senior Vice President , Vice President , Brad Miles , Ben Atwell , Alex Shaw , Takeda Hutchmed New Drug Application Fruquintinib Metastatic Colorectal Cancer Prescription User Fee Act Food And Administration Vegf Receptors Awny Farajallah Phase 3 Fresco Michael Shi Elunate The Journal Of American Medical Association Bsc Esmo ,